Overview: Fine Needle Aspiration Cytology Panel
Introduction: The Fine Needle Aspiration Cytology Panel is a diagnostic tool designed to diagnose mass lesions using aspirate samples. In India, FNAC is widely used for palpable masses (lymph nodes, thyroid, breast, soft tissue), with high diagnostic accuracy for malignancy, infection, or benign lesions. High burden from underutilization in rural areas, limited cytopathology expertise, delayed diagnosis leading to advanced cancer or unnecessary surgery. Per histopathology practices aligned with ICMR and Indian Academy of Cytology guidelines, the test employs microscopy for cytology, cell morphology, and diagnostic opinion over 1-2 days with high specificity, valuable for rapid outpatient diagnosis. This diagnostic falls under cytology screening and targets patients with palpable lumps or imaging-detected masses, addressing accurate detection to guide biopsy, surgery, or conservative management. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing diagnostic delays. Its aspirate-based approach ensures reliable cellular analysis.
Other Names: FNAC Pnl.
FDA Status: FDA approved, CLIA certified for histopathology, compliant with 2025 standards.
Historical Milestone: FNAC minimally invasive standard; in India, essential in oncology clinics.
Purpose: The test assesses 3 parameters including cytology to guide mass lesion diagnosis, evaluate cell morphology, provide diagnostic opinion.
Test Parameters: 1. Cytology, 2. Cell Morphology, 3. Diagnostic Opinion.
Pretest Condition: No fasting required; patients should report palpable mass or imaging abnormality.
Specimen: 1 mL aspirate in 1 sterile container, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 24 hours with proper handling to preserve cell integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate processing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for cytology).
Medical History: Patients should provide details on mass location, duration, pain, fever, family cancer history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed mass including malignancy progression, benefits of early detection, and minimal discomfort from aspiration.
Procedural Considerations: The test involves sample processing using microscopy by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or inadequate aspirate can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal cytology indicates malignancy or infection, necessitating specialist input. Benign result may require follow-up.
Specialist Consultation: Pathologists or oncologists should be consulted for management.
Additional Supporting Tests: Core biopsy, IHC for confirmation.
Test Limitations: May miss sampling errors; comprehensive approach required.
References: Indian Journal of Pathology 2024, FNAC Studies India 2023.
